Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 9,679

Document Document Title
WO/2023/053039A1
Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable ...  
WO/2023/051675A1
The invention concerns compounds of Formula (X) which modulate, especially agonize alpha kinase 1 (ALPK1) and are useful for treating a condition, disease or disorder in which a decrease or increase in ALPK1 activity contributes to the p...  
WO/2023/052468A1
The present application relates to novel nucleoside analogues of formula (I) and compositions containing said nucleoside analogues. Moreover, the present application provides processes for the preparation of the disclosed compounds, as w...  
WO/2023/052970A1
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer, or salt thereof, wherein R1, R2, R3, R4, R5, L1a, L1b, L2, L3, L4, L5, L6, L7, M1, M2, q, w, m ...  
WO/2023/047141A1
Provided herein are analogues of S-adenosyl-L-methionine, methods of their preparation, and complexes and kits comprising the analogues. Said analogues find use in modifying, labelling and analysing a target molecule such as a nucleic acid.  
WO/2023/049258A1
The present disclosure provides to linker compounds of Formula (I) or (II): pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, compounds of formula (l-A) are disclosed. The present disclos...  
WO/2023/041786A1
The invention provides novel 5 -Fluorouracil derivatives that are useful as prodrugs for cancer treatment. 5 -Fluorouracil nucleoside triphosphates are masked at the terminal phosphate of the triphosphate group with residues that are cle...  
WO/2023/039005A2
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.  
WO/2023/034617A1
The present invention is directed to new methods for the treatment of an infection by a virus from the genus Flavivirus, particularly Dengue fever virus, Yellow Fever virus, Zika virus, and West Nile virus, in a host in need thereof, typ...  
WO/2023/031481A1
The present invention relates to a method for preparing cyclic guanosine-3', 5'- monophosphate analogues. The invention also relates to the new cyclic guanosine-monophosphate analogues and intermediates obtained by the method.  
WO/2023/033481A1
The present invention relates to an adenosine diphosphate-ribose (ADP-ribose) binding peptide having anticancer activity and, more particularly, to an ADP-ribose binding peptide of a specific amino acid sequence, a modified product there...  
WO/2023/027178A1
The present invention relates to a method for producing a cytidine-5'-diphosphate compound, the method comprising: (1) a step in which a solution containing a cytidine-5'-diphosphate compound is brought into contact with a basic ion exch...  
WO/2023/026449A1
The purpose of the present invention is to provide a method for producing a cytidine 5'-diphosphate compound, in which cytidine 5'-phosphate can be efficiently separated from a crude cytidine 5'-diphosphate compound to concentrate the cy...  
WO/2023/027065A1
The present invention provides a novel method for producing a 2'-modified guanosine compound represented by the formula. In the formula, R1 and R2 may be the same or different, and each represents a hydrogen atom, an optionally substitut...  
WO/2023/023550A1
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linkage. In some embod...  
WO/2023/021286A2
The present invention relates to novel nucleotide complexes which enhance the enzymatic production of DNA. The nucleotide complexes includes a divalent cation at a ratio of 0.2-1.5 divalent cations per nucleotide, whilst monovalent ions ...  
WO/2023/019670A1
A purification method for fluorescein-labeled nucleoside triphosphate, specifically comprising: purifying a fluorescein-labeled nucleoside triphosphate crude product by means of liquid chromatography, and collecting a target fraction, wh...  
WO/2023/016999A2
GalNAc monomers and GalNAc-oligonucleotide conjugates made using said GalNAc monomers, for example, GalNAc-bearing nucleic acids, e.g. sa-RNAs and siRNAs that may be useful in regulating expression of a target gene.  
WO/2023/017152A1
The present invention relates to novel specific small molecule inhibitors that block KMT9 methyltransferase activity. In particular, the present invention is concerned with a compound of formula (I) wherein X1, X2, X3, X4, R1, R2, R3, R5...  
WO/2023/001982A1
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adduc...  
WO/2023/004130A1
Methods for synthesizing Bisphosphocins use chemical modification of dialcoholic compounds avoiding the use of tetrazole and tertiary butyl hydroperoxide.  
WO/2023/004438A2
The present application provides compounds and methods for identifying a modulator of a protein of interest using TR-FRET donor attached to the protein of interest and a tracer containing TR-FRET acceptor.  
WO/2023/000708A1
Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory eff...  
WO/2023/288045A2
The present disclosure relates monomers and methods for synthesisizing oligonucleotides comprising 2,6-diaminopurine (DAP) and 2-aminoadenine conjugates.  
WO/2023/288047A2
The present disclosure relates generally to monomers and methods for conjugating one or more ligands to oligonucleotides by Click chemistry at the anomeric site of pentose sugars, such as pentose sugars or hexose sugars.  
WO/2023/282306A1
The present invention provides a pharmaceutical composition for treating or preventing a disease associated with the reduction or defect of the modification of 5-taurinomethyluridine (τm5U) in mitochondrial tRNA, the pharmaceutical comp...  
WO/2023/282704A1
The present invention relates to an RNAi agent targeting a mitochondrial amidoxime reducing component 1 (MARC1) gene, and a use thereof, and, more specifically, to: an RNAi agent comprising an antisense strand having sequence complementa...  
WO/2023/280156A1
Provided is a modified nucleoside or nucleotide. The modified nucleoside or nucleotide contains an N or S atom at a 3' position of a sugar ring, and can be used for NGS sequencing. Further provided are a kit comprising the modified nucle...  
WO/2023/277630A1
A galactoside derivative according to the present invention has the effect of inhibiting galectin-3 by having a structure in which a spiro ring is fused to C1, and appropriate substituents at other carbon positions. Therefore, the galact...  
WO/2022/271540A1
This document provides ((benzoimidazolyl)ethyl)cyclobutyl-containing compounds useful in treating cancer such as cholangiocarcinoma.  
WO/2022/271878A1
The invention provides substituted 4-ethynyl-3-hydroxy-tetrahydrofuranyl-adenine phosphoramidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptas...  
WO/2022/265964A1
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 in...  
WO/2022/262845A1
The present disclosure relates to ester derivatives of N 4-hydroxycytidine (NHC), to pharmaceutical compositions thereof, and to the use and method of the ester derivatives of N 4-hydroxycytidine to treat viral infections.  
WO/2022/263489A1
Disclosed herein are base-modified nucleoside-5 '-oligophosphates (bm-N5OP) that include a positively charged moiety at least at one position of the base, compositions comprising the same, compositions made from the same, methods of maki...  
WO/2022/266237A1
Deoxynucleotide prodrugs and methods of their use for treatment of diseases characterized by unbalanced nucleotide pools such as MPV17 and deoxyguanosine kinase deficiency are provided herein.  
WO/2022/265054A1
To provide a hair growth stimulant that is a topical agent exhibiting effects such as promoting hair shaft growth in hairs such as scalp hair, beard hair, eyebrows and/or eyelashes, accelerating gene expression contributing to hair growt...  
WO/2021/209425A9
The present disclosure is directed toward alkynyl nucleoside analogs, compositions comprising these compounds, and their use for treating hepatitis E infections.  
WO/2022/266316A1
Embodiments of the present application relate to N-acetylgalactosamine-conjugated nucleosides. In particular, the N-acetylgalactosamine is installed on the nucleobase of the nucleosides through a wide variety of linkers. Methods of makin...  
WO/2022/266322A1
The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndr...  
WO/2022/258043A1
The present invention provides gemcitabine anticancer derivatives of formula (III) and the anticancer pharmaceutical use, which have the potential to be developed into AKR1C3-activated anticancer drugs.  
WO/2022/260535A1
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodef...  
WO/2022/260336A2
The present invention relates to a nucleoside derivative, which can be used for the prevention or treatment of cancer by inhibiting a kinase, and a pharmaceutical composition comprising same, wherein the nucleoside derivative has inhibit...  
WO/2022/254376A1
The present disclosure provides neoDegraders and neoDegraders conjugated to binding moieties. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., ...  
WO/2022/254457A1
The present invention relates to an improved process for the preparation of (4R)-1-[(2R, 4R, 5R)-3,3-difluoro-4-hydroxy-5- (hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one compound of formula-1 and its intermediate compounds. [F...  
WO/2022/251032A1
A method for purifying nucleotides is provided, that includes preparing a solution comprising (a) 3'-blocked nucleotides, (b) 3'-OH nucleotides, (c) a polishing polymerase, and (d) a template. The polishing polymerase and the template ar...  
WO/2022/248960A1
The present invention relates to solid forms of molnupiravir, including its co-crystals, solvates, hydrates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the same.  
WO/2022/251594A1
The present invention relates to methods for treating a patient infected with hepatitis B virus (HBV) with a therapeutically effective amount of a a phosphoramidate prodrug of clevudine either alone or in combination with a second antivi...  
WO/2022/245814A1
The invention provides methods and compositions for treating medical disorders, such as cancer, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic aci...  
WO/2022/242540A1
Disclosed are a tri-coordinated phosphorus derivative, an intermediate, and a preparation method. The structural formula is as follows: R2 is a phenol group, a pentafluorophenol group, and a C1-4 alkoxy group, and the alkoxy group is opt...  
WO/2022/245584A1
Provided herein are phosphoramidate and cyclophosphate prodrug compounds of unnatural configuration nucleotide, their preparation, and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular path...  

Matches 151 - 200 out of 9,679